It's worth mucking with some revenue assumptions on this with an NPV calculator.
The result changes wildly depending on the assumptions but its a bit of fun.
I assume an 11% discount rate, 10 year project life and a royalty growth from 200K pa to a $3m pa cap after 7 years.
The result I get is something like half of cdy's market cap.
Then there is Advangen/Evolis, the Quest lungdx assay , the Fujukura assay and how the market may value the MK antibody with some progress on trials.
Then there are the current diagnostic trials and collaborations (Abcodia, Japan and around Newcastle). Lots of excitement emerging IMHO.
cheers
peb announcement , page-11
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1457234 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 340000 | 1 |
View Market Depth
| Last trade - 16.12pm 16/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable